Part A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL
Lisata Therapeutics remains a high-risk, pre-revenue entity whose valuation is entirely dependent on the success of its CendR platform, yet the firm faces significant headwinds from persistent operating losses and a rapidly depleting cash position.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 13, 2026 | -$0.73+35.1% vs -$1.13 | — vs $659,000 |
Q3 2026 Aug 6, 2026 | -$0.32 vs — | — vs — |
Q2 2026 May 14, 2026 | -$0.50 vs — | — vs $94,351 |
Q2 2026 Mar 12, 2026 | -$0.74-45.1% vs -$0.51 | $100,000+0.0% vs $100,000 |
Part A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J.
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors. Farrow fills a newly created seat, expanding the board from seven to eight members.
Dyadic International (NASDAQ: DYAI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk. Profitability This table compares Dyadic International and
Benchmark LSTA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Lisata Therapeutics, Inc. (LSTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.04 | $9.47M | -0.56 | -83% | -17159% | -167.79% | — | |
| $1.35 | $171.71M | -2.58 | 14.85% | -96.66% | — | — | |
| $33.21 | $6.85B | -13.49 | — | -7173.52% | -63.01% | — | |
| $3.70 | $150.22M | 6.91 | 55.25% | 58.87% | 6.24% | 27.7% | |
| $10.17 | $855.2M | -14.62 | — | — | -34.98% | — | |
| $35.91 | $1.23B | -6.92 | -43.89% | -339.67% | -29.31% | — |
Lisata Therapeutics, Inc. (LSTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Lisata Therapeutics, Inc. (LSTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 9, 2026·SEC
Aug 4, 2026·SEC
Jul 24, 2026·SEC
Get notified when LSTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lisata Therapeutics, Inc. (LSTA) stock FAQ — growth, dividends, profitability & financials explained
Lisata Therapeutics, Inc. (LSTA) reported $0.1M in revenue over the trailing twelve months. Revenue was $0.2M in fiscal year 2025. That is 99% less than the $21.1M of fiscal year 1995.
Lisata Therapeutics, Inc. (LSTA) revenue fell by 90.7% over the trailing twelve months, compared with the twelve months before.
No. Lisata Therapeutics, Inc. (LSTA) reported a net loss of $17.2M over the trailing twelve months.
Lisata Therapeutics, Inc. (LSTA) had a return on equity (ROE) of -167.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Lisata Therapeutics, Inc. (LSTA) had negative free cash flow of $21.7M over the trailing twelve months.